secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2026-08-25T11:15:43+00:00
Accession:  0001104659-26-100532
Event type: debt
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel gets $1.25M loan, liquidity covenant cut to $250K, must close deal by Aug 31
--------------------------------------------------------------------------------

- Oaktree lenders advanced $1.25M term loan; BioXcel paid $250K upfront fee (20% of principal).
- Minimum liquidity covenant reduced from $3.0M to $250K under Fourteenth Amendment.
- Company must sign definitive agreements by Aug 31, 2026 for full repayment or alternative capital solution.
- Covenants amended to remove flexibility for out-licensing IP and asset sales.
- Amendment includes plan support provisions for potential insolvency proceedings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926100532/0001104659-26-100532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926100532/tm2623945d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-100532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer